CALGARY, ALBERTA--(CCNMatthews - March 21, 2005) - Resverlogix Corp.
("Resverlogix") (TSX:RVX), completes the first stage of its previously
announced Request For Proposal (RFP) process with seven leading global
pharmaceutical organizations for an exclusive standstill agreement
regarding its NEXVAS(TM) technology in Cardiovascular Disease.
